Arrowhead Pharmaceuticals Inc. (ARWR)
73.09
-2.07 (2.75%)
Upcoming Events
Latest Headlines
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
June 2, 2026 7:30 AM - BizWire
Arrowhead presents obesity drug data showing liver fat reduction
May 27, 2026 7:00 AM - StreetInsider
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
May 27, 2026 7:00 AM - BizWire
Arrowhead presents plozasiran data supporting use without dose adjustment
May 26, 2026 10:00 AM - StreetInsider
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
May 26, 2026 10:00 AM - BizWire
Form 144/A ARROWHEAD PHARMACEUTICAL Filed by: Apel Daniel Joseph
May 19, 2026 4:46 PM - SEC Filing
Form 144/A ARROWHEAD PHARMACEUTICAL Filed by: Lu Hongbo
May 19, 2026 4:44 PM - SEC Filing
Form 144/A ARROWHEAD PHARMACEUTICAL Filed by: Hamilton James C
May 19, 2026 4:40 PM - SEC Filing
Form 4 ARROWHEAD PHARMACEUTICAL For: May 12 Filed by: Lu Hongbo
May 14, 2026 7:06 PM - SEC Filing
Arrowhead Pharma (ARWR) PT Raised to $46 at Bernstein SocGen Group
May 13, 2026 7:15 AM - StreetInsider
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Lu Hongbo
May 12, 2026 4:35 PM - SEC Filing
Arrowhead Pharma (ARWR) PT Raised to $87 at RBC Capital
May 8, 2026 7:26 AM - StreetInsider
Form S-8 ARROWHEAD PHARMACEUTICAL
May 7, 2026 5:28 PM - SEC Filing
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31
May 7, 2026 4:07 PM - SEC Filing
Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 11c
May 7, 2026 4:04 PM - StreetInsider
Form 8-K ARROWHEAD PHARMACEUTICAL For: May 07
May 7, 2026 4:03 PM - SEC Filing
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
May 7, 2026 4:01 PM - BizWire
Form SCHEDULE 13G ARROWHEAD PHARMACEUTICAL Filed by: FMR LLC
May 6, 2026 11:02 AM - SEC Filing
Arrowhead licenses liver disease drug to Madrigal for $25 million upfront
May 5, 2026 8:03 AM - StreetInsider
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
May 5, 2026 8:00 AM - BizWire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
May 4, 2026 7:30 AM - BizWire
Arrowhead receives Australia approval for rare disease drug REDEMPLO
May 1, 2026 7:30 AM - StreetInsider
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
May 1, 2026 7:30 AM - BizWire
JPMorgan Starts Arrowhead Pharma (ARWR) at Overweight
May 1, 2026 1:56 AM - StreetInsider
Form SCHEDULE 13G ARROWHEAD PHARMACEUTICAL Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 4:46 PM - SEC Filing
Form SCHEDULE 13G ARROWHEAD PHARMACEUTICAL Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
April 28, 2026 4:06 PM - SEC Filing
Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 22 Filed by: Apel Daniel Joseph
April 24, 2026 6:45 PM - SEC Filing
Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 23 Filed by: Hamilton James C
April 24, 2026 6:39 PM - SEC Filing
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: BlackRock, Inc.
April 24, 2026 4:13 PM - SEC Filing
ARWR receives positive EU opinion for REDEMPLO to treat rare genetic disorder
April 24, 2026 6:39 AM - StreetInsider
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
April 24, 2026 6:39 AM - BizWire
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Hamilton James C
April 23, 2026 7:19 PM - SEC Filing
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Apel Daniel Joseph
April 22, 2026 5:16 PM - SEC Filing
Morgan Stanley Upgrades Arrowhead Pharma (ARWR) to Overweight
April 21, 2026 3:34 AM - StreetInsider
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
April 20, 2026 4:01 PM - BizWire
Arrowhead presents long-term plozasiran data for hypertriglyceridemia
March 30, 2026 4:21 AM - StreetInsider
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Sess
March 28, 2026 10:30 AM - BizWire
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: VANGUARD GROUP INC
March 26, 2026 3:44 PM - SEC Filing
TD Cowen on Arrowhead Pharma (ARWR): 'We remain at Buy as the pipeline remains robust'
March 26, 2026 2:33 PM - StreetInsider
Arrowhead Pharma (ARWR) PT Lowered to $81 at BofA Securities
March 26, 2026 11:12 AM - StreetInsider
Leerink Partners on Arrowhead Pharma (ARWR): SRPT data drives shares up despite IONS pricing update
March 25, 2026 3:05 PM - StreetInsider
Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 19
March 20, 2026 4:05 PM - SEC Filing
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Form 4 ARROWHEAD PHARMACEUTICAL For: Mar 05 Filed by: Hamilton James C
March 9, 2026 7:00 PM - SEC Filing
Full Article List
